Pyruvate Kinase Activators for Hemolytic Anemia Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for pyruvate kinase deficiency (PKD) and other hemolytic anemias are limited, and there is a need for effective activators of the pyruvate kinase R (PKR) enzyme to improve red blood cell function.
Innovation Solution
Development of compounds represented by Formulas (I) to (V) that activate wild type and mutant PKR enzymes, including those with reduced activity, to enhance enzyme function and improve red blood cell health.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for pyruvate kinase deficiency are used, then patient survival is maintained, but red blood cell function is not sufficiently improved
Solution Approach 1:
The patent employs parameter changes by developing small molecule compounds that bind to and activate the pyruvate kinase R enzyme, altering its catalytic activity parameter. The compounds increase enzyme activity in mutant PKR variants, thereby improving red blood cell energy metabolism and reducing hemolytic anemia severity without changing the underlying genetic mutation.
2Adaptability or versatility
If pyruvate kinase R activators are developed, then enzyme activity is enhanced, but treatment options remain limited
Solution Approach 1:
The patent applies universality by designing a series of compounds with a common core structure ( Formula I) that can treat multiple different PKR mutations. The compounds demonstrate broad applicability across various mutant variants, providing a universal treatment approach for pyruvate kinase deficiency rather than mutation-specific therapies.
Solution Approach 2:
The patent systematically varies molecular parameters such as substituent groups (R1-R6), ring structures, and stereochemistry to optimize compound activity while maintaining manageable structural complexity. This allows development of multiple analogs with improved pharmacological properties without excessive structural complexity.
3Reliability
If PKR activator compounds are administered, then red blood cell energy metabolism is improved, but off-target effects may occur
Solution Approach 1:
The patent uses small molecule compounds as intermediaries that specifically bind to the PKR enzyme active site or regulatory regions. These intermediary molecules facilitate enhanced catalytic activity without directly modifying the enzyme structure or requiring genetic intervention, thereby reducing potential off-target effects compared to gene therapy approaches.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The described compounds effectively activate PKR enzymes, leading to improved red blood cell function and potentially reducing the severity of conditions like PKD and other hemolytic anemias.
Implementation Method 1
compounds of Formulas (I), (II), (III), (IV), and (V) that activate pyruvate kinase R (PKR), wild type and/or mutant enzymes
Data Source
AI summary
Described herein are compounds that activate pyruvate kinase, pharmaceutical compositions and methods of use thereof. These compounds are represented by Formula (I) wherein R1, R2, Ra, Rb, Rj, Rk, and Q are as defined herein.